IceCure Medical Regains Nasdaq Compliance Following Reverse Stock Split
Summary
IceCure Medical announced it has regained compliance with the Nasdaq minimum bid price requirement, effectively resolving the delisting threat following its recent reverse stock split.
Key Events
-
Regains Nasdaq Compliance
IceCure Medical received notice from Nasdaq on June 18, 2026, confirming it has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
-
Follows Reverse Stock Split
Compliance was achieved after the company's ordinary shares maintained a closing bid price of $1.00 or greater for 10 consecutive business days, from June 4 to June 17, 2026, following a 1-for-30 reverse stock split effective June 4, 2026.
-
Delisting Threat Removed
The successful regaining of compliance means the bid price deficiency matter is now closed, removing the immediate risk of delisting from Nasdaq.
Analysis
This filing confirms that IceCure Medical has successfully regained compliance with Nasdaq's minimum bid price requirement. This is a critical positive development, as it removes the immediate threat of delisting, which was a significant overhang for the company and its investors. The compliance was achieved after the previously announced 1-for-30 reverse stock split, effective June 4, 2026, boosted the share price above the $1.00 threshold for the required 10 consecutive business days.
At the time of this filing, ICCM was trading at $8.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $26.1M. The 52-week trading range was $2.12 to $42.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.